86 related articles for article (PubMed ID: 2142406)
1. [Transrectal echography and cancer of the prostate. III. Monitoring of the treatment response].
Abad Menor F; Espuela Orgaz R; Pérez Arbej JA; Nogueras Gimeno MA; Martínez Pérez E; Arnaiz Esteban F
Arch Esp Urol; 1990 Apr; 43(3):265-7. PubMed ID: 2142406
[TBL] [Abstract][Full Text] [Related]
2. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
[TBL] [Abstract][Full Text] [Related]
3. [Transrectal echography and cancer of the prostate. I. Echographic characteristics].
Abad Menor F; Espuela Orgaz R; Martínez Pérez E; Pérez Arbej JA; Nogueras Gimeno MA; Arnaiz Esteban F
Arch Esp Urol; 1990 Apr; 43(3):253-7. PubMed ID: 2196004
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of virginal prostatic cancer with cyproterone acetate].
Maier U
Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
[TBL] [Abstract][Full Text] [Related]
5. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
6. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.
Gelet A; Chapelon JY; Bouvier R; Pangaud C; Lasne Y
J Urol; 1999 Jan; 161(1):156-62. PubMed ID: 10037389
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of prostatic cancer with cyproterone acetate].
Maier U
Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
[TBL] [Abstract][Full Text] [Related]
9. The U.S.A. experience: diagnosis and follow-up of prostate malignancy by transrectal ultrasound.
Huben RP
Prog Clin Biol Res; 1987; 237():153-9. PubMed ID: 3317427
[TBL] [Abstract][Full Text] [Related]
10. Transrectal ultrasonography in prostatic carcinoma.
Wozniak-Petrofsky J
Urol Nurs; 1990 Jun; 10(2):12-6. PubMed ID: 2194291
[TBL] [Abstract][Full Text] [Related]
11. [Prostatic cancer: role of echography in the diagnosis, evaluation and surveillance].
Fornage B
Bull Cancer; 1985; 72(5):442-51. PubMed ID: 2416372
[TBL] [Abstract][Full Text] [Related]
12. Transrectal ultrasound in monitoring response to treatment of prostate disease.
Clements R; Griffiths GJ; Peeling WB; Edwards AM
Urol Clin North Am; 1989 Nov; 16(4):735-40. PubMed ID: 2683302
[TBL] [Abstract][Full Text] [Related]
13. [Modification of the echographic pattern of carcinoma of the prostate treated with Lh-rh agonists].
Broseta E; Boronat F; Domínguez C; Vidal J; Llopis B; Jiménez-Cruz JF
Arch Esp Urol; 1989 Mar; 42(2):125-8. PubMed ID: 2660756
[TBL] [Abstract][Full Text] [Related]
14. [Transrectal prostatosonography. Follow-up in prostate cancer therapy].
Dolz M; Drakopoulos A; Aurich B; Frentzel-Beyme B
Z Urol Nephrol; 1985 Sep; 78(9):465-74. PubMed ID: 3907200
[TBL] [Abstract][Full Text] [Related]
15. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
16. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
[TBL] [Abstract][Full Text] [Related]
17. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
18. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
Tauveron I; Hermabessière J
Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
[No Abstract] [Full Text] [Related]
19. [Basic principles and initial results of adjuvant hormone therapy and irradiation of prostatic carcinoma].
Dearnaley DP; Shearer RJ; Ellingham L; Gadd J; Horwich A
Praxis (Bern 1994); 1997 Nov; 86(48):1895-901. PubMed ID: 9480509
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
